
|Articles|June 6, 2019
Syneos Health Consulting Releases Biopharma Dealmakers Survey
Advertisement
Syneos Health Consulting, a biopharmaceutical management consulting firm, released its 11th annual Dealmakers’ Intentions Study. The study indicates there will be an acceleration in dealmaking across all deal types and that buyers seem more willing to accept risk associated with opportunities in the early development and rare disease categories.
To view the study, visit
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons
3
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
4
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
5




